Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature
Lance J. Lyons, Kristi Y. Wu, Keith H. Baratz, Arthur J. Sit
Abstract
Abstract: The Rho kinase inhibitor netarsudil is a recently approved therapeutic option for the management of increased intraocular pressure in the United States. Although phase 3 clinical trials noted corneal changes related to the medication—namely, nonvisually-significant corneal verticillata—descriptions of a unique form of cystic epithelial edema began to surface as netarsudil (and its sister drug ripasudil, approved in Japan) gained widespread use. This series adds 3 new cases and reviews the current literature on this unique side effect.
Topics & Concepts
EdemaMedicineClinical trialRho-associated protein kinaseOphthalmologyDermatologySurgeryKinaseInternal medicineBiologyCell biologyGlaucoma and retinal disordersOcular Infections and TreatmentsIntraocular Surgery and Lenses